You just read:

DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors

News provided by

DelMar Pharmaceuticals, Inc.

Mar 04, 2020, 08:30 ET